Join
Live feed
·
PRReleasevia Quantisnow
Verve Therapeutics Inc. logo

Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia

ByQuantisnow·Wall Street's wire, on your screen.
VERV· Verve Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VERV (Verve Therapeutics Inc.) and more on Quantisnow.